Health
FDA authorizes fingerstick COVID-19 antibody test – Mass Device
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Nirmidas Biotech announced this week that it received FDA emergency use authorization (EUA) for its COVID-19 test in point-of-care settings.
Palo Alto, Calif-based Nirmidas Biotech’s MidaSpot rapid COVID-19 antibody combo detection kit uses fingerstick serology testing to detect IgG/IgM antibodies related to the SARS-CoV-2 virus causing COVID-19, according to a news release.
MidaSpot, touted by Nirmidas as the first point-of-care fingerstick COVID-19 test to receive EUA, can now be administered…
-
General17 hours agoZac Lomax released by Eels for ‘opportunities outside NRL’, fuelling speculation of R360 switch
-
Noosa News23 hours agoSenior constable injured in crash between unmarked police car and stolen vehicle in Pimpama, Queensland
-
Noosa News20 hours agoMore children’s sand products from Kmart and Target recalled over asbestos contamination fears
-
General22 hours agoMore coloured sand products recalled as ACT set to announce when schools will reopen